Home > Formulary : Adult > Recent Decisions > 2018 >
Decisions 16th January 2018
At the meeting on the 16th January the following decisions were agreed:
New Drug Requests
Approved
Trelegy Ellipta® Inhaler (Fluticasone/umeclidinium/vilanterol) (TLS green)
- Approved for inclusion onto the formulary for maintenance treatment of COPD patients.
Not Approved
Saxenda® (Liraglutide)
- Not approved for inclusion onto the formulary for weight management in patients with obesity.
Shared Care Protocols/TLS change in Status
Ciclosporin Eye drops
- TLS change from red to amber. Shared care protocol agreed.
Leflunomide (rheumatology)
- Shared care protocol updated.
Sulfasalazine (rheumatology)
- Shared care protocol updated.
Feraccru®
- Monitoring responsibilities still being clarified. To be uploaded onto website when agreed.
Methylphenidate
- Shared care protocol updated to include preferred brands.
Rotigotine
- Agreed change from TLS amber 1 month to amber no SCP to facilitate timely prescribing by GPs when needed urgently. Shared care protocol to be adapted into prescribing guidance for GPs.
Sodium Valproate/Semi-sodium valproate
- Existing shared care protocol updated to include sodium valproate as preferred first line choice for bipolar disorder and to include clearer MHRA warnings regarding pregnancy.